Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | PNP | P00491 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 4/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12459463 | 0.75 | CYP3A4 (0.67) | KMT2ASMN1; SMN2L3MBTL1MEN1LMNA | |
| SCHEMBL12459461 | 0.73 | KMT2A (0.63) | KMT2ASMN1; SMN2L3MBTL1POLBTHRB | |
| SCHEMBL12459467 | 0.72 | LMNA (0.69) | KMT2APOLBMEN1LMNAMAPT | |
| SCHEMBL1563031 | 0.72 | KMT2A (0.70) | KMT2ASMN1; SMN2L3MBTL1THRBMAPT | |
| SCHEMBL29105155 | 0.71 | KCNQ2 (0.80) | KMT2ASMN1; SMN2L3MBTL1MEN1LMNA | |
| SCHEMBL11919920 | 0.70 | MEN1 (0.62) | KMT2ASMN1; SMN2POLBMEN1MAPT | |
| SCHEMBL4210377 | 0.69 | KMT2A (0.71) | KMT2ASMN1; SMN2USP2MEN1LMNA | |
| SCHEMBL12459696 | 0.69 | CYP3A4 (0.63) | KMT2ASMN1; SMN2L3MBTL1LMNACYP3A4 | |
| SCHEMBL1563417 | 0.68 | KMT2A (0.54) | KMT2AUSP2L3MBTL1MEN1MAPT | |
| SCHEMBL14026814 | 0.68 | KMT2A (0.51) | KMT2ASMN1; SMN2USP2L3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2353593-B1 | Non-nucleoside reverse transcriptase inhibitors | ARDEA BIOSCIENCES INC (US) | 2012-08-22 | — | — | EP | disclosed |
| EP-2353593-B1 | Non-nucleoside reverse transcriptase inhibitors | ARDEA BIOSCIENCES INC (US) | 2012-08-22 | — | — | EP | disclosed |
| EP-2353593-A1 | Non-nucleoside reverse transcriptase inhibitors | Ardea Biosciences, Inc. (US) | 2011-08-10 | — | — | EP | disclosed |
| EP-2353593-A1 | Non-nucleoside reverse transcriptase inhibitors | Ardea Biosciences, Inc. (US) | 2011-08-10 | — | — | EP | disclosed |
| EP-1545483-B1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | ARDEA BIOSCIENCES INC (US) | 2011-04-06 | — | — | EP | disclosed |
| EP-1545483-B1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | ARDEA BIOSCIENCES INC (US) | 2011-04-06 | — | — | EP | disclosed |
| EP-1545483-A4 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | ARDEA BIOSCIENCES INC (US) | 2009-03-25 | — | — | EP | disclosed |
| US-20080249131-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | ARDEA BIOSCIENCES, INC. (US) | 2008-10-09 | — | — | US | disclosed |
| US-20080249131-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | ARDEA BIOSCIENCES, INC. (US) | 2008-10-09 | — | — | US | disclosed |
| US-20080249131-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | ARDEA BIOSCIENCES, INC. (US) | 2008-10-09 | — | — | US | disclosed |
| US-20060135556-A1 | Non-nucleoside reverse transcriptase inhibitors | INTRABIOTICS PHARMACEUTICALS, INC. | 2006-06-22 | — | — | US | disclosed |
| EP-1545483-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | Ribapharm Inc. (US) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004030611-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | RIBAPHARM INC. (US) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249131-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | POLRMT, TYMP, RNGTT | KMT2A 911/4885SMN1; SMN2 1681/4885EGFR 4739/4885 |
| US-20060135556-A1 | Non-nucleoside reverse transcriptase inhibitors | POLRMT, TYMP, RNGTT | KMT2A 911/4885SMN1; SMN2 1681/4885EGFR 4739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.